Medicine & Life Sciences
Netherlands
100%
Cost-Benefit Analysis
45%
Budgets
39%
Health
38%
Lutetium
33%
Income Tax
30%
Vaccination
29%
Costs and Cost Analysis
27%
Orphan Drug Production
26%
Sodium-Glucose Transporter 2 Inhibitors
25%
Symporters
23%
Quality-Adjusted Life Years
23%
Dabigatran
23%
Spinal Muscular Atrophy
22%
Patient Reported Outcome Measures
21%
Octreotide
21%
Immunization Programs
20%
Patient-Centered Care
20%
Neonatal Screening
20%
Indonesia
20%
Delivery of Health Care
20%
Kidney Diseases
20%
Rotavirus
20%
Influenza Vaccines
19%
Neuroendocrine Tumors
19%
Mentoring
19%
Life Cycle Stages
18%
Gross Domestic Product
18%
apixaban
18%
Multiple Myeloma
17%
Rivaroxaban
17%
Psychometrics
16%
Respiratory Tract Infections
16%
Atrial Fibrillation
15%
Disease Outbreaks
15%
Cost Savings
15%
Communicable Diseases
14%
Dialysis
14%
Quality of Life
14%
Health Care Costs
13%
Therapeutics
11%
Uterine Cervical Neoplasms
11%
Continuous Ambulatory Peritoneal Dialysis
10%
Economics
10%
Type 2 Diabetes Mellitus
10%
Guidelines
10%
Renal Dialysis
10%
Reproducibility of Results
9%
Papillomavirus Vaccines
9%
Human Influenza
9%
Social Sciences
Netherlands
62%
costs
50%
eligible patients
30%
dialysis patients
28%
budget
27%
chronic illness
27%
drug
26%
savings
24%
health
22%
orphan
20%
pricing
20%
life years
20%
event
18%
Healthcare
17%
life cycle
17%
contagious disease
17%
quality of life
16%
stroke
16%
Indonesia
14%
psychometrics
14%
health care
12%
information technology
12%
scenario
11%
price level
10%
clinical outcomes
10%
market
9%
cardiovascular disease
9%
market share
8%
economics
8%
performance
7%
evaluation
7%
expert opinions
6%
patent expiry
6%
resources
5%
Clinical Practice
5%
genetic disorders
5%
economic impact
5%
hospitalization
5%
